Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-24T01:24:19.917Z Has data issue: false hasContentIssue false
  • English
  • Français

Realizing Public Rights Through Government Patent Use

Published online by Cambridge University Press:  21 April 2021

Amy Kapczynski
Get access Rights & Permissions [Opens in a new window]

Abstract

A substantial portion of biomedical R&D is publicly funded. But resulting medicines are typically covered by patents held by private firms, and priced without regard to the public’s investment. The Bayh-Dole Act provides a possible remedy, but its scope is limited.

Keywords

PatentsPharmaceuticalsDrug PricingBayh-DoleGovernment Patent Use
Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 49 , Issue 1: Public Sector and Non-Profit Contributions to Drug Development: Historical Scope, Opportunities, and Challenges , Spring 2021 , pp. 34 - 38
Copyright
© 2021 The Author(s)

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

COVID-19 Dashboard, Johns Hopkins Coronavirus Resource Center, available at <https://coronavirus.jhu.edu/map.html>(last visited Sept. 30, 2020).(last+visited+Sept.+30,+2020).>Google Scholar
COVID-19 R&D Tracker Update: 6 Aug. 2020, Policy Cures Research, available at <https://bit.ly/38W5JQD> (last visited Sept. 28, 2020).+(last+visited+Sept.+28,+2020).>Google Scholar
Id.Google Scholar
Beigel, J., Tomashek, K., Dodd, L., Mehta, A., Zingman, B.S., Kalil, A.C., et al., “Remdesivir for the Treatment of Covid-19— Preliminary Report,” New England Journal of Medicine 383 (2020): 1813–1826, available at <https://www.nejm.org/doi/full/10.1056/NEJMoa2007764> (last visited January 7, 2021).CrossRefGoogle Scholar
“COVID-19 Treatment Guidelines: What’s New in the Guidelines,” National Institute of Health, Sept. 1, 2020, available at <https://www.covid19treatmentguidelines.nih.gov/whats-new/> (last visited January 7, 2021).+(last+visited+January+7,+2021).>Google Scholar
Herper, M., “Gilead Announces Long-Awaited Price for Covid-19 Drug Remdesivir,” STAT News, June 29, 2020, available at <https://www.statnews.com/2020/06/29/gilead-announces-remdesivir-price-covid-19/> (last visited July 27, 2020).+(last+visited+July+27,+2020).>Google Scholar
Hill, A., Wang, J., Levi, J., Heath, K., and Fortunak, J., “Minimum Costs to Manufacture New Treatments for COVID-19,” Journal of Virus Eradication 6, no. 2 (2020): 61–69, available at <https://doi.org/10.1016/S2055-6640(20)30018-2> (last visited January 7, 2021).CrossRefGoogle Scholar
“ICER Provides First Update to Pricing Models for Remde-sivir as a Treatment for COVID-19,” Institute for Clinical and Economic Review, June 24, 2020, available at <https://icer-review.org/announcements/updated_icer-covid_models_june_24/> (last visited July 27, 2020).+(last+visited+July+27,+2020).>Google Scholar
Id.Google Scholar
Id.Google Scholar
Rizvi, Z., “Gilead First: How a Monopoly on Remdesivir Led to Rationing,” Public Citizen, Sept. 2, 2020, available at <https://www.citizen.org/article/gilead-first/> (last visited January 7, 2020).+(last+visited+January+7,+2020).>Google Scholar
“Trump Administration Secures New Supplies of Remdesivir for the United States,” U.S. Department of Health and Human Services, June 29, 2020, available at <https://www.hhs.gov/about/news/2020/06/29/trump-administration-secures-new-supplies-remdesivir-united-states.html> (last visited January 7, 2021).+(last+visited+January+7,+2021).>Google Scholar
Rowland, C., “Taxpayers Paid to Develop Remdesivir But Will Have No Say When Gilead Sets the Price,” Washington Post, May 26, 2020, available at <https://www.washingtonpost.com/business/2020/05/26/remdesivir-coronavirus-taxpayers/> (last visited January 7, 2021).+(last+visited+January+7,+2021).>Google Scholar
Sarpatwari, A., Kaltenboeck, A., and Kesselheim, A.S., “Missed Opportunities on Emergency Remdesivir Use,” JAMA 324, no. 4 (2020): 331–332, available at <https://doi.org/10.1001/jama.2020.11932> (last visited January 7, 2021).CrossRefGoogle Scholar
Id.Google Scholar
Krellenstein, J., Morten, C.J., The U.S. Government’s Apparent Co-Ownership of Patents Protecting Remdesivir (2020), available at <https://www.prep4all.org/news/remdesivir> (last visited January 7, 2021).CrossRef+(last+visited+January+7,+2021).>Google Scholar
Id.Google Scholar
Li, D., Azoulay, P., and Sampat, B.N., “The Applied Value of Public Investments in Biomedical Research,” Science 356, no. 6333 (2017): 78–81.CrossRefGoogle Scholar
Thomas, J.R., “March-In Rights Under the Bayh-Dole Act,” Congressional Research Service, Aug. 22, 2016, available at <https://fas.org/sgp/crs/misc/R44597.pdf> (last visited January 7, 2021).+(last+visited+January+7,+2021).>Google Scholar
Id.Google Scholar
35 U.S.C. § 201(e) (2018).CrossRefGoogle Scholar
35 U.S.C. § 203(a) (2018).Google Scholar
Bayh, B. and Dole, R., “Our Law Helps Patients Get New Drugs Sooner,” Washington Post, April 11, 2002, at A28.Google Scholar
Thomas, supra note 19.Google Scholar
Rowland, C., “Trump Administration Makes It Easier for Drug-makers to Profit from Publicly Funded Coronavirus Drugs, Advocates Say,” Washington Post, July 1, 2020, available at <https://www.washingtonpost.com/business/2020/07/01/vaccine-coronavirus-barda-trump/> (last visited July 27,2020).+(last+visited+July+27,2020).>Google Scholar
Rowland, supra note 13.Google Scholar
Brennan, H., Kapczynski, A., Monahan, C.H., and Rizvi, Z., “A Prescription for Excessive Drug Pricing: Leveraging Government Patent Use for Health,” Yale Journal of Law and Technology 18 (2016): 275–354.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
Beigel, supra note 4.Google Scholar
Supra note 8.Google Scholar